Catrina Mugglin1, Janne Estill, Gilles Wandeler, Nicole Bender, Matthias Egger, Thomas Gsponer, Olivia Keiser. 1. Division of International and Environmental Health, Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland Department of Infectious Diseases, University Hospital Bern, Bern, Switzerland School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Abstract
OBJECTIVES: To assess the proportion of patients lost to programme (died, lost to follow-up, transferred out) between HIV diagnosis and start of antiretroviral therapy (ART) in sub-Saharan Africa, and determine factors associated with loss to programme. METHODS: Systematic review and meta-analysis. We searched PubMed and EMBASE databases for studies in adults. Outcomes were the percentage of patients dying before starting ART, the percentage lost to follow-up, the percentage with a CD4 cell count, the distribution of first CD4 counts and the percentage of eligible patients starting ART. Data were combined using random-effects meta-analysis. RESULTS: Twenty-nine studies from sub-Saharan Africa including 148,912 patients were analysed. Six studies covered the whole period from HIV diagnosis to ART start. Meta-analysis of these studies showed that of the 100 patients with a positive HIV test, 72 (95% CI 60-84) had a CD4 cell count measured, 40 (95% CI 26-55) were eligible for ART and 25 (95% CI 13-37) started ART. There was substantial heterogeneity between studies (P < 0.0001). Median CD4 cell count at presentation ranged from 154 to 274 cells/μl. Patients eligible for ART were less likely to become lost to programme (25%vs. 54%, P < 0.0001), but eligible patients were more likely to die (11%vs. 5%, P < 0.0001) than ineligible patients. Loss to programme was higher in men, in patients with low CD4 cell counts and low socio-economic status and in recent time periods. CONCLUSIONS: Monitoring and care in the pre-ART time period need improvement, with greater emphasis on patients not yet eligible for ART.
OBJECTIVES: To assess the proportion of patients lost to programme (died, lost to follow-up, transferred out) between HIV diagnosis and start of antiretroviral therapy (ART) in sub-Saharan Africa, and determine factors associated with loss to programme. METHODS: Systematic review and meta-analysis. We searched PubMed and EMBASE databases for studies in adults. Outcomes were the percentage of patients dying before starting ART, the percentage lost to follow-up, the percentage with a CD4 cell count, the distribution of first CD4 counts and the percentage of eligible patients starting ART. Data were combined using random-effects meta-analysis. RESULTS: Twenty-nine studies from sub-Saharan Africa including 148,912 patients were analysed. Six studies covered the whole period from HIV diagnosis to ART start. Meta-analysis of these studies showed that of the 100 patients with a positive HIV test, 72 (95% CI 60-84) had a CD4 cell count measured, 40 (95% CI 26-55) were eligible for ART and 25 (95% CI 13-37) started ART. There was substantial heterogeneity between studies (P < 0.0001). Median CD4 cell count at presentation ranged from 154 to 274 cells/μl. Patients eligible for ART were less likely to become lost to programme (25%vs. 54%, P < 0.0001), but eligible patients were more likely to die (11%vs. 5%, P < 0.0001) than ineligible patients. Loss to programme was higher in men, in patients with low CD4 cell counts and low socio-economic status and in recent time periods. CONCLUSIONS: Monitoring and care in the pre-ART time period need improvement, with greater emphasis on patients not yet eligible for ART.
Keywords:
Afrique subsaharienne; liens avec les soins; linkage to care; loss to follow‐up; mortalidad; mortality; mortalité; nexo con atención médica; perte au suivi; pre‐ART; pre‐TAR; pré‐ART; pérdida durante el seguimiento; sub‐Saharan Africa; África subsahariana
Authors: Charles F Gilks; Siobhan Crowley; René Ekpini; Sandy Gove; Jos Perriens; Yves Souteyrand; Don Sutherland; Marco Vitoria; Teguest Guerma; Kevin De Cock Journal: Lancet Date: 2006-08-05 Impact factor: 79.321
Authors: Bruce A Larson; Alana Brennan; Lynne McNamara; Lawrence Long; Sydney Rosen; Ian Sanne; Matthew P Fox Journal: Bull World Health Organ Date: 2010-04-16 Impact factor: 9.408
Authors: R A Murphy; H Sunpath; B Taha; S Kappagoda; K T M Maphasa; D R Kuritzkes; L Smeaton Journal: Int J Tuberc Lung Dis Date: 2010-07 Impact factor: 2.373
Authors: Margaret May; Andrew Boulle; Sam Phiri; Eugene Messou; Landon Myer; Robin Wood; Olivia Keiser; Jonathan A C Sterne; Francois Dabis; Matthias Egger Journal: Lancet Date: 2010-07-15 Impact factor: 79.321
Authors: Elena Losina; Ingrid V Bassett; Janet Giddy; Senica Chetty; Susan Regan; Rochelle P Walensky; Douglas Ross; Callie A Scott; Lauren M Uhler; Jeffrey N Katz; Helga Holst; Kenneth A Freedberg Journal: PLoS One Date: 2010-03-04 Impact factor: 3.240
Authors: Katharina Kranzer; Jennifer Zeinecker; Philip Ginsberg; Catherine Orrell; Nosindiso N Kalawe; Stephen D Lawn; Linda-Gail Bekker; Robin Wood Journal: PLoS One Date: 2010-11-02 Impact factor: 3.240
Authors: Elvin H Geng; Mwebesa B Bwana; Jerome Kabakyenga; Winnie Muyindike; Nneka I Emenyonu; Nicholas Musinguzi; Peter Mugyenyi; Jeffrey N Martin; David R Bangsberg Journal: PLoS One Date: 2010-11-24 Impact factor: 3.240
Authors: Jennifer M Gilvydis; Wayne T Steward; Parya Saberi; John Tumbo; Jeri Sumitani; Scott Barnhart; Sheri A Lippman Journal: AIDS Care Date: 2015-08-17
Authors: Larry W Chang; Gertrude Nakigozi; Veena G Billioux; Ronald H Gray; David Serwadda; Thomas C Quinn; Maria J Wawer; Robert C Bollinger; Steven J Reynolds Journal: AIDS Behav Date: 2015-10
Authors: Elisabeth M Schaffer; Juan Marcos Gonzalez; Stephanie B Wheeler; Dalsone Kwarisiima; Gabriel Chamie; Harsha Thirumurthy Journal: Appl Health Econ Health Policy Date: 2020-06 Impact factor: 2.561
Authors: Alastair van Heerden; Danielle M Harris; Heidi van Rooyen; Ruanne V Barnabas; Nithya Ramanathan; Nkosinathi Ngcobo; Zukiswa Mpiyakhe; W Scott Comulada Journal: Soc Sci Med Date: 2017-04-26 Impact factor: 4.634
Authors: Njoroge Anne; Matthew D Dunbar; Felix Abuna; Peter Simpson; Paul Macharia; Bourke Betz; Peter Cherutich; David Bukusi; Farquhar Carey Journal: Int J Med Inform Date: 2019-10-18 Impact factor: 4.046
Authors: Gertrude Nakigozi; Fredrick E Makumbi; John B Bwanika; Lynn Atuyambe; Steven J Reynolds; Godfrey Kigozi; Fred Nalugoda; Larry W Chang; Valerian Kiggundu; David Serwadda; Maria J Wawer; Ronald H Gray; Moses R Kamya Journal: J Acquir Immune Defic Syndr Date: 2015-09-01 Impact factor: 3.731